Facebook Thread Authored By: Hiroyuki Kuromitsu (Hiro)
Once again, just checking early morning news and chatter on Facebook, and another interesting article rears it’s head.
I am Just learning about this site:
Click to view source article
Images in Cardiovascular Medicine
Five-Year Optical Coherence Tomography Follow-Up of an Everolimus-Eluting Bioresorbable Vascular Scaffold
Changing the Paradigm of Coronary Stenting?
- Antonios Karanasos, MD;
- Cihan Simsek, MD;
- Patrick Serruys, MD, PhD;
- Jurgen Ligthart, BSc;
- Karen Witberg, CCRN;
- Robert-Jan van Geuns, MD, PhD;
- George Sianos, MD, PhD;
- Felix Zijlstra, MD, PhD;
- Evelyn Regar, MD, PhD
+ Author Affiliations
From the Department of Interventional Cardiology, Thoraxcentre, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Correspondence to Evelyn Regar, MD, PhD, Department of Cardiology, Thoraxcentre, BA-585, Erasmus University Medical Centre, ‘s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. E-mail email@example.com
A 58-year-old man, included in cohort A of the Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions (ABSORB) trial,1 had undergone implantation of a bioresorbable everolimus-eluting scaffold (BVS; Abbott Vascular, Santa Clara, CA) in June 2006 because of stable angina class III with a positive exercise test (Figure 1). He had a positive family history for coronary artery disease. At implantation, his total cholesterol was 207 mg/dL, his low-density lipoprotein level was 130 mg/dL, and his high-density lipoprotein level was 71 mg/dL. Coronary angiography revealed a single lesion at the middle left anterior descending artery that was treated with a 3.0×12 mm BVS, and he was discharged on a treatment regimen of dual antiplatelet therapy (aspirin clopidogrel) for 6 months and atorvastatin 20 mg. His lipid profile 2 years after implantation showed a total cholesterol of 144.3 mg/dL, a low-density lipoprotein level of 65 mg/dL, and a high-density lipoprotein level of 60 mg/dL.
Coronary angiography of the left anterior descending artery before (A and B) and after (C and D) intervention at baseline. White arrows in panels C and D indicate the radio-opaque markers at the edge of the stent.
The patient was asymptomatic with a negative exercise test at a 5-year follow-up in March 2012. Repeat coronary angiography as part of a local study protocol did not demonstrate any significant lesions at the site of the previous BVS implantation in the left anterior descending (Figure 2C and 2D). Optical coherence tomography evaluation of the target segment did not reveal any struts at the vascular wall (Movie I in the online-only Data Supplement). Minimal lumen area inside the scaffold had increased by 22.1% (4.51 to 5.51 mm2) from 6 months to 5 years (Figure 3). Reference vessel diameter had increased from 2.96 mm at 6 months to 3.02 mm at 5 years. Evaluation of specific regions over the site of a calcified plaque showed complete resorption of struts at 5 years that had showed an open box or bright box appearance at 6 months’ follow-up, whereas the thickness of the intimal layer shielding the calcified tissue from the lumen had significantly increased (baseline, 10 μm; 6 months, 260 μm; 5 years, 200 μm) (Figure 4). Using dedicated online software (qAngioOCT, Medis Medical Imaging Systems bv, Leiden, Netherlands), 3-dimensional optical coherence tomography rendering illustrates the patent, smooth lumen surface throughout the treated vessel segment (Figure 5 and Movie II in the online-only Data Supplement).
Repeat angiography demonstrating the site of implantation in the left anterior descending artery at 6 months (A and B) and 5 years (C and D) after implantation. White arrows indicate the radio-opaque markers at the edge of the stent, and the black lines indicate the sites corresponding to the cross-sectional images of Figure 3.
Optical coherence tomography images from matched sites at 6 months (both St. Jude/Lightlab M3 time domain optical coherence tomography [OCT] system; A and C) and 5 years (D and F) after stent implantation (St. Jude/Ligthlab C7XR Fourier domain OCT system). Panel B represents the site of the minimal lumen area (4.51 mm2) at 6 months, whereas panel E represents the site of the minimal lumen area at 5 years (5.51 mm2). Lumen area also was increased at the matched sites from 6 months to 5 years (5.31 mm2 [A] versus 7.45 mm2 [D]; 5.09 mm2 [C] versus 6.43 mm2 [F]). Note the complete disappearance of the scaffold struts at the 5-year follow-up, as well as the regular contour of the lumen as opposed to the 6-month follow-up.
Images acquired from a matched site (panels C and F of Figure 3) at baseline (A), 6 months (B), and 5 years (C). The amount of tissue overlying the calcific deposition has increased from baseline to 6 months because of scaffold implantation and the associated neointimal response. At 5 years, the scaffold struts and neointima have merged into a thick layer of tissue covering the underlying plaque. Arrowheads indicate scaffold struts. GW indicates guide wire artifact.
Three-dimensional reconstruction of cross-sectional images corresponding to the segment where the scaffold was placed (green markers). Arrows indicate the location of the cross-sectional images of Figure 3.
This is the first human case demonstrating the complete resorption in vivo of a BVS scaffold 5 years after implantation. Using optical coherence tomography, we observed the complete absence of struts in the vascular wall together with an increase of the minimal lumen area by 22.1%. This is in line with previous human studies that have demonstrated the temporal course of the polymer degradation at 6 months and 2 years,1 as well as an increase in luminal area due to a decrease in plaque size without change in vessel size, whereas studies in a porcine experimental model have demonstrated complete resorption of the polymer 4 years after implantation.2
Importantly, we observed in our patient the development of a homogenous, bright, signal-intense layer shielding the persistent signal-poor, sharply delineated calcified plaque toward the lumen. Conceptually, such tissue growth could be protective because it potentially could diminish the risk of plaque erosion or rupture and prevent thrombogenic plaque components (such as calcified nodules, as in our patient, or necrotic core) from coming in direct contact with the blood stream.3 Of note, this effect on the vascular wall did not come at the cost of lumen narrowing in our patient; luminal dimensions in the target segment increased from 6 months to 5 years. Such potentially favorable tissue response, as witnessed in this case, might hold promise for the future, evoking the utopia of a passivation of potentially unstable plaques by local therapeutic intervention.
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.112.110122/-/DC1.
- © 2012 American Heart Association, Inc.
- Serruys PW,
- Ormiston JA,
- Onuma Y,
- Regar E,
- Gonzalo N,
- Garcia-Garcia HM,
- Nieman K,
- Bruining N,
- Dorange C,
- Miquel-Hebert K,
- Veldhof S,
- Webster M,
- Thuesen L,
- Dudek D
. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.
- Onuma Y,
- Serruys PW,
- Perkins LE,
- Okamura T,
- Gonzalo N,
- Garcia-Garcia HM,
- Regar E,
- Kamberi M,
- Powers JC,
- Rapoza R,
- van Beusekom H,
- van der Giessen W,
- Virmani R
. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122:2288–2300.